Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease
| Status: | Recruiting |
|---|---|
| Conditions: | Anemia, Urology |
| Therapuetic Areas: | Hematology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 8 - 21 |
| Updated: | 3/8/2019 |
| Start Date: | January 2016 |
| End Date: | December 2025 |
| Contact: | Kerry A Morrone, MD |
| Email: | kmorrone@montefiore.org |
| Phone: | 718-741-2342 |
Desmopressin as a Therapy for Nocturnal Enuresis in Patients With Sickle Cell Disease
This study assesses if using the medication desmopressin will decrease nightime bedwetting in
children with sickle cell disease. Half of the children will receive placebo and half of the
children will receive desmopressin, with the option to prescribe desmopressin as soon as the
study is completed.
children with sickle cell disease. Half of the children will receive placebo and half of the
children will receive desmopressin, with the option to prescribe desmopressin as soon as the
study is completed.
Night time bedwetting is a common complication of sickle cell disease, and affects up to 30 %
of children . Desmopressin is an oral medication that increases water reabsorption in the
kidneys. Studies have shown that it is effective in decreasing bedwetting episodes in
children without sickle cell disease. Chronic sickling episodes causing damage to the kidneys
could cause permanent damage and may make this treatment ineffective in sickle cell disease.
The investigators designed this trial to definitively answer this question by randomizing the
patients to give half of the children placebo and the other half titrated doses of
desmopressin. This trial will inform pediatric sickle cell doctors if desmopressin is an
appropriate treatment for bed wetting in the investigators patients.
of children . Desmopressin is an oral medication that increases water reabsorption in the
kidneys. Studies have shown that it is effective in decreasing bedwetting episodes in
children without sickle cell disease. Chronic sickling episodes causing damage to the kidneys
could cause permanent damage and may make this treatment ineffective in sickle cell disease.
The investigators designed this trial to definitively answer this question by randomizing the
patients to give half of the children placebo and the other half titrated doses of
desmopressin. This trial will inform pediatric sickle cell doctors if desmopressin is an
appropriate treatment for bed wetting in the investigators patients.
Inclusion Criteria:
1. Patients with Hemoglobin SS, SC, SB0thal or SB+thal
2. Patients with at least two episodes of primary nocturnal enuresis per week or four
episodes over the two weeks prior to enrollment.
3. Patients with secondary enuresis who have been evaluated and cleared by a pediatric
urologist as not having other etiologies of enuresis (e.g. overactive detrusor
activity, a genitourinary anatomic abnormality)
Exclusion Criteria:
1. Patients with developmental delay or neurologic dysfunction secondary to stroke.
2. Patients with hypertension or underlying renal disease.
3. Patients with genitourinary anatomic abnormalities. Any prior renal ultrasound showing
normal genitourinary anatomy is sufficient to clear a patient for the study.
4. Patients with daytime urinary incontinence
5. Patients with glucosuria on urinalysis.
6. Patients with secondary nocturnal enuresis who have not been evaluated by a pediatric
urologist to rule out other etiologies of enuresis.
7. Patients who are pregnant.
8. Patients receiving another medicine for nocturnal enuresis (e.g. imipramine).
We found this trial at
1
site
Click here to add this to my saved trials
